A Phase 2 interventional study of gemcitabine and gemcitabine in Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Completed at 13 sites in Japan. Open to female participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2010-03-17.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.
Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 45th largest by enrollment of the 90 interventional ones that give a count, is one of 5 that started in 2005, is one of 65 in phase 2, and was the 22nd registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Margaret Gatti-Mays · Sites in United States
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 20 Years to 74 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 73 · Phase 3 19
First in 1997; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is close to the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 90 interventional studies. Of the 78 that completed or were terminated, 34 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 95 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 60th largest by enrollment of the 80 interventional ones that give a count, is one of 6 that started in 2005, is one of 41 in phase 2, and was the 11th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
1 of the studies testing gemcitabine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06026657Margaret Gatti-MaysGemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies testing gemcitabine in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
To investigate efficacy, safety and PK of GEM monotherapy after prior chemotherapy with anthracycline and taxane regimen for patients with metastatic breast cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose Level 1 - 1000 mg/m2
Drug: gemcitabine
Dose Level 2 - 1250 mg/m2
Drug: gemcitabine
1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
Also known as: LY188011, Gemzar
1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
Also known as: LY188011, Gemzar
Tumor Response
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.
Time frame: baseline to measured progressive disease
Duration of Response
For responders, the minimum and maximum of the duration of complete response, duration of partial response, and duration of overall response were summarized, and the median of response duration and its 95% confidence interval were calculated using the Kaplan-Meier estimation.
Time frame: time of response to progressive disease
Time to Progressive Disease
Time from study enrollment to first date of disease progression. Time to disease progression was censored at date of death if death was due to other cause. The minimum and maximum of this parameter were summarized, and the median time to progression and its 95% confidence interval were calculated using the Kaplan-Meier estimation.
Time frame: baseline to measured progressive disease
Survival at 1 Year
Results are reported as number of participants alive at one year.
Time frame: baseline to date of death from any cause, evaluate at 1 year
Pharmacokinetics - Normalized Cmax
maximum gemcitabine plasma concentration normalized to 1250 milligrams per square meter of gemcitabine.
Time frame: cycle 1
Pharmacokinetics - Normalized Area Under the Curve
Area under the gemcitabine plasma concentration-time curve from time zero to infinity. Gemcitabine dose was normalized to 1250 milligrams per square meter.
Time frame: cycle 1
| Milestone | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Started | 6 | 62 |
| Completed | 0 | 4 |
| Not completed | 6 | 58 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Adverse event | 1 | 4 |
| Withdrew: Progression of disease | 4 | 42 |
| Withdrew: Lack of efficacy | 1 | 5 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Pathologic aggrevation | 0 | 1 |
| Withdrew: Physician decision | 0 | 3 |
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.
| participants | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Complete Response | 0 | 1 |
| Partial Response | 0 | 4 |
| Long Stable Disease | 1 | 4 |
| Stable Disease | 1 | 16 |
| Progressive Disease | 2 | 32 |
| Not Evaluable | 2 | 5 |
For responders, the minimum and maximum of the duration of complete response, duration of partial response, and duration of overall response were summarized, and the median of response duration and its 95% confidence interval were calculated using the Kaplan-Meier estimation.
| months | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Duration of Response | — | 10.07 (5.43 to 13.80) |
Time from study enrollment to first date of disease progression. Time to disease progression was censored at date of death if death was due to other cause. The minimum and maximum of this parameter were summarized, and the median time to progression and its 95% confidence interval were calculated using the Kaplan-Meier estimation.
| days | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Time to Progressive Disease | 137 (97 to 196) | 92 (78 to 121) |
Results are reported as number of participants alive at one year.
| participants | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Survival at 1 Year | 4 | 42 |
maximum gemcitabine plasma concentration normalized to 1250 milligrams per square meter of gemcitabine.
| nanograms per milliliter (ng/mL) | Dose Normalized to 1250 Milligrams Per Square Meter |
|---|---|
| Pharmacokinetics - Normalized Cmax | 29,036 (16,341 to 53,857) |
Area under the gemcitabine plasma concentration-time curve from time zero to infinity. Gemcitabine dose was normalized to 1250 milligrams per square meter.
| nanograms times hour per milliliter | Dose Normalized to 1250 Milligrams Per Square Meter |
|---|---|
| Pharmacokinetics - Normalized Area Under the Curve | 15,999 (9,929 to 21,723) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level 1 | — | — | — |
| Dose Level 2 | — | — | — |
| Event | Dose Level 1 | Dose Level 2 |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/6 | 0/62 |
| CellulitisInfections and infestations | 1/6 | 1/62 |
| Catheterisation venousSurgical and medical procedures | 0/6 | 2/62 |
| Blood lactate dehydrogenase increasedInvestigations | 0/6 | 1/62 |
| InfectionInfections and infestations | 0/6 | 1/62 |
| Femur fractureMusculoskeletal and connective tissue disorders | 0/6 | 1/62 |
| Cardiac failure acuteCardiac disorders | 0/6 | 1/62 |
| AnorexiaMetabolism and nutrition disorders | 0/6 | 1/62 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/6 | 1/62 |
| Brain oedemaNervous system disorders | 0/6 | 1/62 |
| Event | Dose Level 1 | Dose Level 2 |
|---|---|---|
| Neutrophil count decreasedInvestigations | 2/6 | 26/62 |
| Alanine aminotransferase increasedInvestigations | 1/6 | 8/62 |
| AnorexiaMetabolism and nutrition disorders | 1/6 | 1/62 |
| Aspartate aminotransferase increasedInvestigations | 0/6 | 4/62 |
| NauseaGastrointestinal disorders | 0/6 | 3/62 |
| VomitingGastrointestinal disorders | 0/6 | 3/62 |
| MalaiseGeneral disorders | 0/6 | 1/62 |
| PyrexiaGeneral disorders | 0/6 | 1/62 |
| NasopharyngitisInfections and infestations | 0/6 | 1/62 |
| C-reactive protein increasedInvestigations | 0/6 | 1/62 |
| Age Continuous(years) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Mean | 53.3 ± 7.45 | 52.4 ± 11.25 | 52.5 ± 10.93 |
| Sex: Female, Male(Participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Female | 6 | 62 | 68.0 |
| Male | 0 | 0 | 0.0 |
| Region of Enrollment(participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| Japan | 6 | 62 | 68.0 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| 0 - Fully Active | 4 | 45 | 49.0 |
| 1 - Ambulatory, Restricted Strenuous Activity | 2 | 17 | 19.0 |
| Human Epidermal Growth Factor Receptor 2 Expression Status(participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| 0 | 2 | 27 | 29.0 |
| 1+ | 1 | 20 | 21.0 |
| 2+ | 2 | 4 | 6.0 |
| 3+ | 1 | 9 | 10.0 |
| Unknown | 0 | 2 | 2.0 |
| Presence of Estrogen Hormone Receptor(participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| None | 4 | 25 | 29.0 |
| Present | 2 | 37 | 39.0 |
| Unknown | 0 | 0 | 0.0 |
| Presence of Metastasis(participants) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| None | 0 | 5 | 5.0 |
| Lung | 0 | 27 | 27.0 |
| Bone | 1 | 24 | 25.0 |
| Liver | 2 | 25 | 27.0 |
| Brain | 0 | 0 | 0.0 |
| Lymph Node | 2 | 23 | 25.0 |
| Skin | 1 | 6 | 7.0 |
| Other Sites | 0 | 13 | 13.0 |
| Presence of Progesterone Hormone Receptor(participant) | Dose Level 1 | Dose Level 2 | Total |
|---|---|---|---|
| None | 3 | 39 | 42.0 |
| Present | 2 | 23 | 25.0 |
| Unknown | 1 | 0 | 1.0 |
4 further baseline measures are reported on the registry.
The record gives a start of Jun 2005, a primary completion of Mar 2008 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gemcitabine